These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

653 related items for PubMed ID: 12559808

  • 1. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects.
    Squarcione S, Sgricia S, Biasio LR, Perinetti E.
    Vaccine; 2003 Mar 07; 21(11-12):1268-74. PubMed ID: 12559808
    [Abstract] [Full Text] [Related]

  • 2. [Comparative study on safety and immunogenicity between influenza subunit vaccine and split vaccine].
    Dong PM, Li YQ, Zheng TZ, Jia YP, Li F, Han TW, Qiao RX, Zhang BH.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Jul 07; 24(7):570-3. PubMed ID: 12975010
    [Abstract] [Full Text] [Related]

  • 3. Comparison between a conventional subunit vaccine and the MF59-adjuvanted subunit influenza vaccine in the elderly: an evaluation of the safety, tolerability and immunogenicity.
    Sindoni D, La Fauci V, Squeri R, Cannavò G, Bacilieri S, Panatto D, Gasparini R, Amicizia D.
    J Prev Med Hyg; 2009 Jun 07; 50(2):121-6. PubMed ID: 20099444
    [Abstract] [Full Text] [Related]

  • 4. [Study on the safety and immunogenicity of MF59-adjuvanted influenza subunit vaccine in Chinese elderly].
    Li RC, Fang HH, Li YP, Liu YP, Nong Y, Huang GB.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Jun 07; 29(6):548-51. PubMed ID: 19040034
    [Abstract] [Full Text] [Related]

  • 5. Comparison of the immunogenicity and safety of the conventional subunit, MF59-adjuvanted, and intradermal influenza vaccines in the elderly.
    Seo YB, Choi WS, Lee J, Song JY, Cheong HJ, Kim WJ.
    Clin Vaccine Immunol; 2014 Jul 07; 21(7):989-96. PubMed ID: 24828092
    [Abstract] [Full Text] [Related]

  • 6. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly.
    De Donato S, Granoff D, Minutello M, Lecchi G, Faccini M, Agnello M, Senatore F, Verweij P, Fritzell B, Podda A.
    Vaccine; 1999 Aug 06; 17(23-24):3094-101. PubMed ID: 10462245
    [Abstract] [Full Text] [Related]

  • 7. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial.
    Nicholson KG, Abrams KR, Batham S, Clark TW, Hoschler K, Lim WS, Medina MJ, Nguyen-Van-Tam JS, Read RC, Warren FC, Zambon M.
    Lancet Infect Dis; 2011 Feb 06; 11(2):91-101. PubMed ID: 21168369
    [Abstract] [Full Text] [Related]

  • 8. A Phase III randomised trial of the immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in adult and elderly subjects, assessing both anti-haemagglutinin and virus neutralisation antibody responses.
    van de Witte S, Nauta J, Montomoli E, Weckx J.
    Vaccine; 2018 Sep 25; 36(40):6030-6038. PubMed ID: 29709447
    [Abstract] [Full Text] [Related]

  • 9. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study.
    Waddington CS, Walker WT, Oeser C, Reiner A, John T, Wilkins S, Casey M, Eccleston PE, Allen RJ, Okike I, Ladhani S, Sheasby E, Hoschler K, Andrews N, Waight P, Collinson AC, Heath PT, Finn A, Faust SN, Snape MD, Miller E, Pollard AJ.
    BMJ; 2010 May 27; 340():c2649. PubMed ID: 20508026
    [Abstract] [Full Text] [Related]

  • 10. A randomised, partially observer blind, multicentre, head-to-head comparison of a two-dose regimen of Baxter and GlaxoSmithKline H1N1 pandemic vaccines, administered 21 days apart.
    Nicholson KG, Abrams KR, Batham S, Clark TW, Hoschler K, Lim WS, Medina M, Nguyen-Van-Tam JS, Read RC, Warren FC, Zambon M.
    Health Technol Assess; 2010 Dec 27; 14(55):193-334. PubMed ID: 21208550
    [Abstract] [Full Text] [Related]

  • 11. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.
    Vesikari T, Kirstein J, Devota Go G, Leav B, Ruzycky ME, Isakov L, de Bruijn M, Oberye J, Heijnen E.
    Lancet Respir Med; 2018 May 27; 6(5):345-356. PubMed ID: 29631857
    [Abstract] [Full Text] [Related]

  • 12. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly.
    Ruf BR, Colberg K, Frick M, Preusche A.
    Infection; 2004 Aug 27; 32(4):191-8. PubMed ID: 15293073
    [Abstract] [Full Text] [Related]

  • 13. Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines.
    Andrews NJ, Walker WT, Finn A, Heath PT, Collinson AC, Pollard AJ, Snape MD, Faust SN, Waight PA, Hoschler K, Sheasby L, Waddington C, Kerridge S, Chalk J, Reiner A, John T, Fletcher M, Allen R, Fineman N, Wilkins S, Casey M, Michaelis L, Oeser C, Okike I, Ladhani S, Miller E.
    Vaccine; 2011 Oct 19; 29(45):7913-9. PubMed ID: 21875635
    [Abstract] [Full Text] [Related]

  • 14. A 1-year follow-on study from a randomised, head-to-head, multicentre, open-label study of two pandemic influenza vaccines in children.
    de Whalley P, Walker W, Snape MD, Oeser C, Casey M, Moulsdale P, Harrill C, Andrews N, Hoschler K, Thompson B, Jones C, Chalk J, Kerridge S, Tomlinson R, Heath PT, Finn A, Faust S, Miller E, Pollard AJ.
    Health Technol Assess; 2011 Dec 19; 15(45):v-vi, xi-xiii, 1-128. PubMed ID: 22257497
    [Abstract] [Full Text] [Related]

  • 15. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications.
    Baldo V, Baldovin T, Floreani A, Carraro AM, Trivello R, Family Medicine Group of Pianiga.
    Vaccine; 2007 May 16; 25(20):3955-61. PubMed ID: 17383057
    [Abstract] [Full Text] [Related]

  • 16. Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59-adjuvanted influenza vaccine in infants and young children.
    Nolan T, Bravo L, Ceballos A, Mitha E, Gray G, Quiambao B, Patel SS, Bizjajeva S, Bock H, Nazaire-Bermal N, Forleo-Neto E, Cioppa GD, Narasimhan V.
    Vaccine; 2014 Oct 21; 32(46):6146-56. PubMed ID: 25223266
    [Abstract] [Full Text] [Related]

  • 17. Immunogenicity and safety of a novel seasonal influenza preservative-free vaccine manufactured in Kazakhstan: Results of a randomized, comparative, phase II clinical trial in adults.
    Sarsenbayeva G, Volgin Y, Kassenov M, Issagulov T, Bogdanov N, Sansyzbay A, Stukova M, Buzitskaya Z, Кulmagambetov I, Davlyatshin T, Khairullin B.
    Hum Vaccin Immunother; 2018 Mar 04; 14(3):609-614. PubMed ID: 29112488
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults.
    Frey S, Poland G, Percell S, Podda A.
    Vaccine; 2003 Oct 01; 21(27-30):4234-7. PubMed ID: 14505903
    [Abstract] [Full Text] [Related]

  • 19. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine.
    Podda A.
    Vaccine; 2001 Mar 21; 19(17-19):2673-80. PubMed ID: 11257408
    [Abstract] [Full Text] [Related]

  • 20. Similar immunogenicity of the A/H1N1 2009 pandemic influenza strain when used as a monovalent or a trivalent vaccine.
    Van der Vliet D, Pepin S, Lambert M, Fauchoux N, Donazzolo Y, Dupuy M, Dakowski C, Denis M.
    Hum Vaccin; 2010 Oct 21; 6(10):823-8. PubMed ID: 20935517
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.